Insulet Corporation (PODD)
NASDAQ: PODD · Real-Time Price · USD
282.80
-5.49 (-1.90%)
Feb 21, 2025, 4:00 PM EST - Market closed
Insulet Revenue
In the year 2024, Insulet had annual revenue of $2.07B with 22.07% growth. Insulet had revenue of $597.50M in the quarter ending December 31, 2024, with 17.20% growth.
Revenue (ttm)
$2.07B
Revenue Growth
+22.07%
P/S Ratio
9.57
Revenue / Employee
$690,533
Employees
3,000
Market Cap
19.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.07B | 374.50M | 22.07% |
| Dec 31, 2023 | 1.70B | 391.80M | 30.02% |
| Dec 31, 2022 | 1.31B | 206.50M | 18.79% |
| Dec 31, 2021 | 1.10B | 194.40M | 21.49% |
| Dec 31, 2020 | 904.40M | 166.20M | 22.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
PODD News
- 20 hours ago - Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst - Benzinga
- 1 day ago - Insulet Corporation (PODD) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Insulet beats quarterly profit estimates on insulin pump demand - Reuters
- 1 day ago - Insulet Reports Full Year 2024 Revenue Increase of 22% and Fourth Quarter 2024 Revenue Increase of 17% Year-Over-Year - Business Wire
- 5 weeks ago - Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe - Business Wire
- 6 weeks ago - Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 - Business Wire
- 2 months ago - Heavy Interest in Insulet's Insulin Delivery Device - FXEmpire
- 2 months ago - Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case - Reuters